Reported 2 days ago
Regeneron Pharmaceuticals, Inc. (REGN) received a ‘Hold’ rating from Wells Fargo, which set a stock price target of $580 due to the company's shifting growth strategy. Key analyst Mohit Bansal pointed out that the resubmission of the Eylea HD pre-filled syringe for FDA review is unlikely to have a significant financial impact, as Eylea's older formula saw a drastic sales decline. While Regeneron’s newer products like Dupixent are performing well, regulatory delays continue to weigh on investor sentiment, prompting a cautious outlook amidst short-term challenges.
Source: YAHOO